TRINITY BIOTECH (JOINT VENTURE) LIMITED

Trinity Biotech (Joint Venture) Limited is a public, internationally-focused company specialising in the development, manufacture and marketing of clinical diagnostic products. Drawing on deep scientific expertise, the business delivers high-performance solutions that enable laboratories and healthcare providers to detect and monitor a range of conditions quickly and accurately.

Key offerings include the Premier Resolution HPLC analyser, designed for precise thalassaemia and haemoglobin variant detection, and the Bartels® FlexTrans™ Transport Medium, which suppresses microbial contamination during specimen transport. The portfolio also features a single-use immunoassay for rapid detection of HIV-1 and HIV-2 antibodies, as well as emerging services such as the FDA-cleared PreClara™ pre-eclampsia test and a breakthrough continuous glucose-monitoring sensor. Recent regulatory approvals have paved the way for off-shored manufacturing of its flagship rapid HIV test, strengthening both strategic and financial performance.

While the company's operations span global markets-including the United States-its core mission remains the same: to provide reliable, innovative diagnostic tools that improve patient outcomes and support the evolving needs of the healthcare community.